• Company
• oHCM drug Camzyos's last hurdle to reimb remains high
• by Eo, Yun-Ho Oct 15, 2024 05:50am

• Company
• “Market for veterinary drugs expected to grow rapidly”
• by Son, Hyung Min Oct 15, 2024 05:50am

• Policy
• Reduced reimb for medicines-containing choline alfoscerate
• by Lee, Tak-Sun Oct 15, 2024 05:49am

• Policy
• Will generics dominate the oral psoriasis treatment market?
• by Lee, Tak-Sun Oct 14, 2024 05:49am

• Policy
• NA-MFDS clash on the approval of abortion pills
• by Lee, Jeong-Hwan Oct 14, 2024 05:49am

• Policy
• Approval process for 'Leqembi' heavily debated
• by Lee, Hye-Kyung Oct 14, 2024 05:49am

• Policy
• Drug pricing negotiations for Qarziba gather pace
• by Lee, Tak-Sun Oct 14, 2024 05:49am

• Company
• Dong-A ST’s biosimilar first enters the U.S. market
• by Chon, Seung-Hyun Oct 14, 2024 05:49am

• Company
• ERT demonstrates effectiveness in treating Fabry disease
• by Whang, byung-woo Oct 11, 2024 06:25am

• Company
• ‘Switching between AD drugs’ discussed at NA audit
• by Whang, byung-woo Oct 11, 2024 05:54am